• TiGenix NV, of Leuven, Belgium, and its subsidiary Cellerix SA, of Tres Cantos, Spain, will receive about $3.8 million from the European Seventh Framework Programme to support the development of their Cx611 program of allogeneic expanded adipose-derived stem cells to treat rheumatoid arthritis.